Published in AIDS on March 13, 2016
Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings. J Int AIDS Soc (2016) 0.83
Attitudes and perceptions towards novel objective measures of ARV-based vaginal ring use: Results from a global stakeholder survey. PLoS One (2017) 0.75
Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single dose vaginal gel administration. Antimicrob Agents Chemother (2017) 0.75
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
pplacer: linear time maximum-likelihood and Bayesian phylogenetic placement of sequences onto a fixed reference tree. BMC Bioinformatics (2010) 5.70
Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One (2012) 2.79
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One (2013) 2.39
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses (2013) 1.76
Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception (2005) 1.52
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
Optimization of media for detection of hydrogen peroxide production by Lactobacillus species. J Clin Microbiol (2003) 1.45
Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav (2012) 1.35
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. AIDS (2012) 1.10
More than meets the eye: associations of vaginal bacteria with gram stain morphotypes using molecular phylogenetic analysis. PLoS One (2013) 1.07
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. J Acquir Immune Defic Syndr (2015) 0.93
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob Agents Chemother (2013) 0.92
Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures. J Acquir Immune Defic Syndr (2015) 0.89
Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. AIDS Res Hum Retroviruses (2015) 0.84
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology (2013) 0.84
Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur J Contracept Reprod Health Care (2002) 0.82
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41
Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol (2011) 3.30
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One (2012) 2.79
Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ Microbiol (2008) 2.73
Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One (2010) 2.62
Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis (2007) 2.57
The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis (2009) 2.56
Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis (2005) 2.55
Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis (2007) 2.42
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
Burden of asthma in inner-city elementary schoolchildren: do school-based health centers make a difference? Arch Pediatr Adolesc Med (2003) 2.18
Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.15
Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal (2011) 2.10
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One (2011) 2.00
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis (2011) 1.94
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One (2011) 1.84
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis (2009) 1.81
Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.78
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses (2013) 1.76
PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS (2007) 1.75
Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis (2006) 1.72
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav (2013) 1.72
Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis (2008) 1.70
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother (2004) 1.69
RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses (2012) 1.67
Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat Immunol (2012) 1.65
Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol (2006) 1.64
Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med (2002) 1.60
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med (2008) 1.59
Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci (2009) 1.58
Herpes simplex virus triggers activation of calcium-signaling pathways. J Cell Biol (2003) 1.58
Cultivation of Tropheryma whipplei from cerebrospinal fluid. J Infect Dis (2003) 1.58
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS (2002) 1.58
Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol (2004) 1.58
The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn Microbiol Infect Dis (2006) 1.54
PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis (2005) 1.54
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis (2007) 1.48
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One (2010) 1.46
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr (2008) 1.43
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS (2004) 1.42
Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients. Pediatr Transplant (2011) 1.40
Impact of surveillance stool culture guided selection of antibiotics in the management of pediatric small bowel transplant recipients. Pediatr Transplant (2006) 1.39
Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am J Reprod Immunol (2010) 1.37
Validation data-based adjustments for outcome misclassification in logistic regression: an illustration. Epidemiology (2011) 1.35
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics (2009) 1.33
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr (2015) 1.32
Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol (2008) 1.32
Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother (2005) 1.31
Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis (2005) 1.29
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater (2009) 1.28
Menopause symptoms in HIV-infected and drug-using women. Menopause (2005) 1.27
Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. J Gen Virol (2002) 1.27
Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol (2008) 1.26
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
HIV infection, drug use, and onset of natural menopause. Clin Infect Dis (2005) 1.24
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med (2014) 1.24
Focal adhesion kinase plays a pivotal role in herpes simplex virus entry. J Biol Chem (2005) 1.24
Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol (2009) 1.24
Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.24
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther (2009) 1.24
PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther (2009) 1.24
Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl (2002) 1.23
Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS (2007) 1.22
Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells. J Virol (2006) 1.22
Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis (2005) 1.22
Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr (2004) 1.21
Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci (2008) 1.20
Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol (2007) 1.19
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res (2010) 1.19
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J Clin Immunol (2011) 1.16
Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.16
Comparison of quantitative real time PCR with Sequencing and ribosomal RNA-FISH for the identification of fungi in formalin fixed, paraffin-embedded tissue specimens. BMC Infect Dis (2011) 1.14
Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res (2013) 1.12
Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther (2009) 1.12
The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. Bioanalysis (2013) 1.11
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal (2013) 1.11
Multiple receptor interactions trigger release of membrane and intracellular calcium stores critical for herpes simplex virus entry. Mol Biol Cell (2007) 1.10